Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin Plus Weekly Docetaxel in Recurrent or Metastatic Nasopharyngeal Cancer
NCT01312311Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jul 2006
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Samsung Medical Center. Primary endpoint: Objective Response Rate at 6 months. Status: unknown.
02
Drugs
docetaxelcisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT01312311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01312311.